The primary aim of this study was to verify if a fully integrated, real-time PCR-based Idylla system can be used for the rapid determination of NRAS mutation status in patients with serous borderline ovarian tumors and low-grade serous ovarian carcinomas. Here, NRAS is linked to ovarian serous carcinoma.